在一座国际医药创新园（BioPark）内，阿斯利康第六个全球战略研发中心正式启用，搭建起连接中英 医药创新的新桥梁。 10月25日，在2025国际生物医药产业创新北京论坛期间，阿斯利康正式启用位于北京经济技术开发区 （简称"北京经开区"，亦称"北京亦庄"）BioPark的第六个全球战略研发中心。当日，北京－剑桥－阿 斯利康科学创新生态合作签约，一个阿斯利康与和铂医药用于开展研究合作的全新实验室同步启用。这 一系列成果的落地，标志着北京亦庄在打造全球生物医药创新资源高地进程中迈出关键一步，通过"研 发中心－平台赋能－生态圈建设"联动，进一步强化从研发到平台到生态圈建设的全链条能力，为区域 高质量发展注入强劲动能。 阿斯利康英国主席Shaun Grady介绍，本次合作的理念为"3C"。其一为连接（Connect），阿斯利康将汇 聚专家与专业力量，在北京与剑桥之间构建双向联系。在本次合作框架下，北京合作方将于今年年底首 次访问剑桥，而剑桥也将派出一支资深、有能力且具有影响力的代表团，预计于明年春季访问北京，旨 在使各方汇聚一堂；其二为交流（Communicate），培训教育项目将涵盖政策内容，推动创新成果转化 为具 ...

Core Insights - AstraZeneca has officially launched its sixth global strategic R&D center in Beijing, establishing a new bridge for Sino-British pharmaceutical innovation [1] - The collaboration between AstraZeneca and Cambridge University aims to enhance connectivity, communication, and collaboration in the pharmaceutical sector, marking a new phase in Sino-British cooperation [3] - China's pharmaceutical industry is undergoing rapid transformation, driven by innovation and increasing integration into the global clinical trial landscape [4] Group 1: AstraZeneca's R&D Center and Collaborations - The new R&D center in Beijing is part of a broader strategy to strengthen the entire innovation ecosystem, enhancing capabilities from research to platform and ecosystem development [1] - The "3C" concept (Connect, Communicate, Collaborate) is central to the partnership, focusing on building trust and facilitating deeper discussions on specific research areas [3] - AstraZeneca's collaboration with Harbour BioMed in oncology and autoimmune diseases is expected to inject new momentum into drug development through a diversified cooperation model [10] Group 2: China's Pharmaceutical Innovation Landscape - The "Healthy China 2030" strategy emphasizes high-quality healthcare services and the unique advantages of pharmaceuticals, driving the rapid growth of innovative drugs [4] - By 2024, Chinese companies are expected to account for 30% of global clinical trial initiations, reflecting China's growing influence in the global clinical trial arena [4] - The increasing number of innovative drugs included in the medical insurance directory is driving the rapid growth of the original innovative drug market in China [4] Group 3: Future of Sino-British Cooperation - The partnership between AstraZeneca and local entities in Beijing represents a new model of innovation cooperation, leveraging the strengths of both sides [5] - The collaboration aims to create a comprehensive innovation ecosystem that connects early-stage research to clinical applications, enhancing the global competitiveness of Chinese pharmaceutical innovations [10][14] - The shift from simple product cooperation to a more advanced collaborative model signifies China's transition from being a "world pharmacy" to a global source of pharmaceutical innovation [14]